Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2

BACKGROUND: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven to be a successful strategy for prevent severe infections. CoronaVac and BNT162b2 are the most used vaccines worldwide, but their use in heterologous vaccination schedules is still subjected to ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Rammauro, Florencia, Carrión, Federico, Olivero-Deibe, Natalia, Fló, Martín, Ferreira, Ana, Pritsch, Otto, Bianchi, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352561/
https://www.ncbi.nlm.nih.gov/pubmed/35907676
http://dx.doi.org/10.1016/j.vaccine.2022.07.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352561/
https://www.ncbi.nlm.nih.gov/pubmed/35907676
http://dx.doi.org/10.1016/j.vaccine.2022.07.023

Ejemplares similares